Morris James LLP is investigating claims on behalf of patients who developed cutaneous T-cell lymphoma (CTCL) after being prescribed Dupixent® (dupilumab), a drug marketed for the treatment of eczema, asthma, chronic sinusitis with nasal polyps, and eosinophilic esophagitis.
Recent scientific studies have reported that Dupixent® patients may face a significantly higher risk of CTCL, a rare and aggressive form of non-Hodgkin lymphoma that is often mistaken for eczema in its early stages. Reports indicate that the drug may mask early signs of CTCL or accelerate the disease, delaying diagnosis and treatment. The lawsuits allege that manufacturers Sanofi and Regeneron failed to adequately warn patients and healthcare providers of the potential cancer risks associated with the drug.
Morris James is pursuing justice for patients and families affected by Dupixent® nationwide. Potential claims may allow patients and families to recover compensation for medical expenses, lost wages, pain and suffering, and, in tragic cases, wrongful death.
Patients who have taken Dupixent® and later developed CTCL are encouraged to contact Morris James for a free, confidential consultation online or by calling 302.655.2599.
“Patients trusted Dupixent® to help manage chronic conditions. Instead, many were blindsided by a life-altering cancer diagnosis. Our attorneys are committed to holding drug manufacturers accountable to vulnerable patients.” - Morris James Managing Partner Keith Donovan
